PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation extraction kits; IntelliPlex platform that is designed for pCode technology with for sample-to-answer multiplexing assays; oncology kits for lung cancer and mutation detection, as well as rearrangements; IntelliPlex SARS-CoV-2 detection test kits/flu kits and IntelliPlex SARS-CoV-2 variant analysis kits; and pCode coupling buffer sets. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan.
Metrics to compare | 6572 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6572PeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.5x | −140.6x | −0.6x | |
PEG Ratio | −2.38 | −1.68 | 0.00 | |
Price/Book | 2.9x | 6.4x | 2.6x | |
Price / LTM Sales | 6.1x | 8.9x | 3.4x | |
Upside (Analyst Target) | - | 0.0% | 41.3% | |
Fair Value Upside | Unlock | −13.4% | 4.9% | Unlock |